Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2013 - 2026)

Ocular Therapeutix has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $14.0 million in Q2 2026.

• Non-Current Deffered Revenue for Q2 2026 came in at $14.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $14.0 million (changed 0.0% YoY), and the FY2025 annual result was $14.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $14.0 million in Q2 2026, from $14.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $14.3 million in Q2 2023 and troughed at $13.0 million in Q2 2022.
• A 5-year average of $13.8 million and a median of $14.0 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The widest annual swing landed in 2022, when Non-Current Deffered Revenue climbed 12.78%; it then fell 1.78% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $13.4 million in 2022, then rose by 5.59% to $14.1 million in 2023, then declined by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $14.0 million in Q2 2026, $14.0 million in Q1 2026, and $14.0 million in Q4 2025.